Table 1.
Demographic and Clinical Features of Patients with Multiple sclerosis.
| Features | n (n:30) | % |
|---|---|---|
| Medications DP | ||
| Interferon 1A | 10 | 33.3 |
| Interferon 1B | 10 | 33.3 |
| Mycophenolatmofetil | 2 | 6.6 |
| Fingolimod | 2 | 6.6 |
| Dimethylfumarat | 2 | 6.6 |
| Natalizumab | 2 | 6.6 |
| Rituximab | 2 | 6.6 |
| Regular medication intake | ||
| Before pandemic | 29 | 96,6 |
| During the pandemic | 26 | 86.7 |
| Regular Workout/Physical Exercise | ||
| Before pandemic | 9 | 30 |
| During pandemic | 5 | 16.6 |
| Regular Balanced Diet DP | 19 | 63.3 |
| Weight Gain DP | 13 | 43.3 |
| Concern of Risk Increase DP | 24 | 80 |
| Disruption of Doctor Checks DP | 21 | 70 |
| Decrease in Exposure to Sunlight DP | 22 | 73.3 |
| Vitamin D intake – starting in DP | 13 | 43.3 |
| Increased exposure to smoking DP | 3 | 10 |
| Having attack DP | 3 | 10 |
DP: During Pandemic.